small molecule

OXBRYTA

VOXELOTOR

Loss of exclusivityOctober 2037latest FDA-listed patent expiry

CompanyGLOBAL BLOOD THERAPEUTICS INC

Drug detail

Brand name	OXBRYTA
Active ingredient	VOXELOTOR
Strength	300MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	October 2022
Marketing status	DISCN

Listed patents

Patent	Expires	Type
10493035	October 2037	product
11944612	December 2036	use U-3893
11020382	December 2036	use U-3134
10722502	February 2035	product
11452720	February 2035	use U-3459
9447071	February 2035	substance, product
9248199	January 2034	use U-2715
9018210	November 2033	substance, product
10034879	December 2032	substance, product
10806733	December 2032	substance
10017491	December 2032	product

Regulatory exclusivity

Code	Expires
ODE-394	December 2028

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from GLOBAL BLOOD THERAPEUTICS INC